Immunosuppressants drugs for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
SAVE-MORE NCT04680949		RCT	anakinra	placebo	COVID 19 hospitalized	low	412/194	conclusif	suggested 55 % decrease in deaths with a high degree of certainty due to low risk of bias demonstrated 64 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
COVID-19 mild to moderate meta-analysis
LIVE-AIR (Temesgen) NCT04351152		RCT	lenzilumab	placebo	COVID-19 mild to moderate	some concern	261/259	conclusif	demonstrated 35 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
COVID-19 severe or critically meta-analysis
CAN-COVID NCT04362813		RCT	canakinumab	placebo	COVID-19 severe or critically	some concern	227/227	inconclusive	inconclusive 39 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 mild to moderate meta-analysis

COVID-19 severe or critically meta-analysis